BioSpace News Archive

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation in the 10 th Annual SVB Leerink Global Healthcare Conferen

BrainsWay Ltd., a global leader in the advanced non-invasive treatment of brain disorders, announced the addition of Fran Hackett as Vice President of North American Sales effective February 16, 2021.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced it has dosed the first patient in its Phase 2b/3 VOICE trial of Validive ® for the prevention of chemoradiotherapy-induced severe oral mucositis in pat ents with oropharyngeal cancer (VOICE).

PolyPid Ltd. announced that the 100th patient has been enrolled and randomized in the SHIELD I trial, the Company’s first of two Phase 3 clinical trials for its lead product candidate, D-PLEX100, for the prevention of post-abdominal surgery incisional infections.

Creative Medical Technology Holdings, Inc. announced filing of a patent application covering the use of ImmCelz® regenerative cell therapy for preventing rejection of transplanted organs.

REBLOZYL®, an erythroid maturation agent, is the first and only of its kind approved for use in Canada

PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, announced the appointment of Guillermina Lozano, Ph.D., to its Scientific Advisory Board.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2020 financial results and operational highlights following the close of U.S. financial markets on Monday, March 1, 2021.

Kala Pharmaceuticals Announces EYSUVIS ™ Now Covered by Express Scripts Express Scripts coverage effective February 5, 2021 WATERTOWN, Mass.--( BUSINESS WIRE )-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Express Scripts, one of the leading pharmacy benefit managers (PBM) in the United States, h

bluebird bio, Inc. (Nasdaq: BLUE) announced today that the company has placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD) (bb1111) on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML).